Browse the corpus

Contact urticaria is a transient wheal-and-flare response to exposure to specific agents, especially in the work environment. Contact urticaria falls into three types: immune-mediated, non-immune-mediated, and contact urticaria due to an unknown mechanism. This activity reviews the etiology, types, pathophysiology, evaluation, and treatment of contact urticaria and protein contact dermatitis. This activity highlights the role of the interprofessional team in managing patients with contact urticaria. Objectives: Describe the types of occupations most at risk for developing contact urticaria. Describe the pathogenesis of contact urticaria. Describe the clinical presentation and management of protein contact dermatitis. Describe the testing algorithm in the diagnosis of contact urticaria and outline the management of patients with contact urticaria. Access free multiple choice questions on this topic.

Contact urticaria (CU) is a transient wheal-and-flare reaction that occurs within 10 to 60 minutes at the site of contact with the offending agent and completely resolves within 24 hours. It was first described in 1973 by Alexander Fischer. It is a form of acute urticaria (symptoms last for less than six weeks).

The risk of developing CU increases when the stratum corneum is disrupted by filaggrin gene mutations or skin irritants. The common agents implicated in the development of CU are presented in the following sections. The occupations at the highest risk of developing CU are healthcare, laboratory work, agriculture, hairdressing, the cosmetics industry, the chemical industry, cleaning, construction, catering, cooking, electronics, machinery, and metal products.[1][2][3]

The prevalence in the general population remains unrecognized due to lower diagnostic rates. The prevalence of occupational CU is 0.4%, accounting for 30% of all occupational skin diseases. Research indicates a prevalence of 5% to 10% for latex-related CU.[3] The prevalence of sensitization to natural rubber latex (NRL) among healthcare workers is between 5% to 13%.[4][5][6] NRL, cosmetics, skin creams, and sorbic acid are some of the most common causative agents identified.[7][8][4][9] The Finnish Registry indicated that the incidence of CU had more than doubled between 1989 and 1994, with cow dander, NRL, flour, and grains as common triggers.[7]

CU is classified based on the pathophysiology into: Immunologic CU (ICU) Non-immunologic CU (NICU) CU due to unknown mechanisms 1. Immunologic CU (ICU) ICU involves antigen binding to IgE-specific antibodies (type I hypersensitivity reaction) on the dermal mast cells. After antigen-antibody binding, histamine and vasoactive mediators such as prostaglandins and leukotrienes are released, resulting in disruption of the skin microcirculation. A stronger allergic response than in non-immunologic CU (NICU) is elicited due to the ready absorption of proteins through the skin [10]. Prior sensitization to the agent is necessary for the reaction to develop. Repeated exposure to the antigen can lead to progressive worsening of symptoms. A concomitant history of other atopic disorders, such as personal or family history of asthma, eczema, and hay fever, is a risk factor.[11] The reaction spreads beyond the site of initial contact and progresses to generalized urticaria, even leading to anaphylactic shock. This progression of symptoms in a step-wise manner has been described in four stages as 'contact urticaria syndrome.' Stage 1- Localized urticaria (redness and swelling), dermatitis, and some non-specific symptoms like burning, itching, tingling, etc Stage 2- Generalized urticaria Stage 3- Systemic manifestations like bronchial asthma, angioedema, rhinitis, conjunctivitis, oropharyngeal symptoms (Ex, lip swelling, hoarseness, difficulty in swallowing), gastrointestinal symptoms (Ex.nausea, vomiting, diarrhea, abdominal cramps) Stage 4- Generalized anaphylactic reaction, including anaphylactic shock There are two broad categories of agents causing ICU.[11] High molecular weight proteins with a molecular weight of more than 10000 kD. Ex. dietary proteins. Hapten chemicals with molecular weight less than 1000 kD: They conjugate with carrier proteins like albumin and form the hapten-carrier protein complex. Ex. Di-isocyanate is used in polyurethane products, and ammonium persulfate. The agents causing ICU can be divided into 4 groups.[8][2] Group I - Plant-derived proteins (eg, vegetables, fruits, spices) Group II- Animal-derived proteins (Ex.meat, dairy products, seafood) Group III- Grains (Ex, wheat, barley, rye) Group IV- Enzymes (Ex, alpha-amylase, cellulase, xylanase) 2. Non-immunologic CU (NICU)

Hapten chemicals with molecular weight less than 1000 kD: They conjugate with carrier proteins like albumin and form the hapten-carrier protein complex. Ex. Di-isocyanate is used in polyurethane products, and ammonium persulfate. The agents causing ICU can be divided into 4 groups.[8][2] Group I - Plant-derived proteins (eg, vegetables, fruits, spices) Group II- Animal-derived proteins (Ex.meat, dairy products, seafood) Group III- Grains (Ex, wheat, barley, rye) Group IV- Enzymes (Ex, alpha-amylase, cellulase, xylanase) 2. Non-immunologic CU (NICU) NICU is less severe and more common than ICU. There are no specific antibodies against the causative agents. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the response, showing that prostaglandins (Ex, prostaglandin D2) may play a role in the pathogenesis.[12][10][13][14][15] Histamine has not been shown to play a role since antihistamines did not have any inhibitory effect. Other proposed mechanisms include direct capillary damage at the site of contact, leading to the non-IgE-mediated release of vasoactive amines, prostaglandins, leukotrienes, and acetylcholine.[8][12][10][13][14] Unlike ICU, there are no systemic manifestations, and the reaction remains localized. Prior exposure to the antigen is not necessary, and it can present on initial skin contact with the allergen. The symptoms vary depending on the site of exposure, the concentration of the substance, and the mode of exposure.[16] NICU agents can be classified into the following types: Animals (Ex, arthropods, caterpillars, corals) Foods (Ex, pepper, mustard, thyme) Fragrances and flavorings (Ex, balsam of Peru, cinnamic acid, cinnamic aldehyde) Medications (Ex, benzocaine, camphor, witch-hazel) Metals (Ex, cobalt) Plants (Ex, nettles, seaweed) Preservatives and disinfectants (Ex, benzoic acid, formaldehyde) Described in Table 1 are some of the common causative agents for NICU. There is an overlap in the causative agents between the ICU and the NICU. 3. CU due to an unknown mechanism Some reactions of CU have unknown mechanisms that remain unclassified. Ammonium persulfate is a classic example of this type of response. The CUE due to ammonium persulphate can be mediated by the classical pathway (IgG- or IgM-mediated) or by the type 1 (IgE-mediated) pathway. Protein contact dermatitis

3. CU due to an unknown mechanism Some reactions of CU have unknown mechanisms that remain unclassified. Ammonium persulfate is a classic example of this type of response. The CUE due to ammonium persulphate can be mediated by the classical pathway (IgG- or IgM-mediated) or by the type 1 (IgE-mediated) pathway. Protein contact dermatitis Protein contact dermatitis (PCD) was first described in kitchen workers with localized dermatitis of the hands and forearms. PCD is chronic hand eczema that occurs in contact with proteins, with or without a positive prick test.[17] The pathophysiology involves repeated microtrauma to the skin, leading to penetration by large protein molecules. It involves a type I, type IV, or delayed-phase type I hypersensitivity reaction. The reaction occurs within minutes of contact, but only 15% reported an immediate-type hypersensitivity reaction.[17][18] Those who react to specific dietary proteins rarely present with systemic symptoms on oral ingestion.[19] The proteins can spread from the hands to contact sites, including the face or abdomen.[19][18][20]

When a patient presents to the office with symptoms and signs suggestive of CU, a thorough history and clinical examination aid in the accurate diagnosis. Clinical history: In addition to general history-taking, the clinician should pay particular attention to the history of exposure to potential causative agents in food, home/work environments, cosmetics, and personal care products. The temporal relationship between the time of exposure and the development of symptoms, and the time to resolution of symptoms, is necessary information. Also include aggravating factors (ie, temperature changes, physical pressure, etc.) and relieving factors like medications in history. Obtain details on the specific skin symptoms (eg, wheals, tingling, burning, itching) and their progression. A personal and family history of atopy helps make the diagnosis of IgE-mediated ICU. Volatile proteins can cause signs and symptoms of conjunctivitis, rhinitis, or asthma when they come in contact with the mucosa of the conjunctiva or respiratory tract (Ex, flour). Other systemic symptoms, such as abdominal pain, mouth itching on oral ingestion (oral allergy syndrome), and diarrhea, may develop upon contact with the gastrointestinal mucosa. Physical examination: Clinical presentation is commonly a wheal-and-flare response with urticarial swelling. Patients affected by CU can present with hives (urticaria) or dermatitis (eczema). The urticarial response appears as an erythematous swelling with surrounding pallor. In a NICU reaction, the typical wheal-and-flare response may be absent. The skin examination should focus on the site of involvement, the pattern of distribution, size, shape, and confluence of lesions, as well as angioedema, erythema, pallor, dermographism, and urticarial vasculitis. CU wheals do not blister, and scaling is generally not seen. They remain transient, with no residual skin changes or pigmentation.[21] The diagnostic signs are different during an active flare vs. a period of quiescence. PCD presents as recurrent dermatitis with urticarial plaques or vesicles. The vesicles can develop rapidly and progress to erythematous-squamous or erythematous-vesicular lesions.[22] Paronychia with periungual edema and erythema can be a sign of PCD.[23]

In vivo and in vitro methods are useful for diagnostic evaluation, in addition to history and physical examination. Skin tests are quick to perform and considered relatively safe. In-vivo test In vivo tests are most commonly used for the diagnosis of CU.  Clinical supervision with the provision to handle an impending anaphylactic shock is necessary. Both ICU and NICU reactions occur within 15 to 20 minutes or can be delayed. If testing on intact skin is negative, then previously affected skin sites are used. Positive test results require careful correlation with clinical symptoms. Medications like antihistamines, NSAIDs, and exposure to ultraviolet light can cause false-negative results. The patient should be off antihistamines for 48 hours before testing. See Figure 1 for the diagnostic algorithm for testing immediate contact reactions.[6][24] Prick test: It is considered the test of choice for the diagnosis of ICU. The inner aspect of the forearm is the preferred site, and multiple allergens can undergo testing simultaneously, using positive control with histamine and negative control with normal saline with results interpreted in 30 minutes. False-positive results occur due to a positive reaction from one test site spreading to the neighboring site or an irritant reaction. PCD can be diagnosed with a prick test. If skin prick tests and serum allergen-specific IgE tests are negative, a provocation or direct challenge test may be needed. Open test/ skin provocation test: The open test is used for the diagnosis of NICU. The test consists of gently rubbing 0.1ml of the test substance over a 3 cm x 3 cm area of intact skin on the volar aspect of the forearm. The site requires an examination at 20, 40, and 60 minutes. The best vehicle for testing the agents is an alcohol-water or alcohol propylene glycol mixture. Use test: The test agent in the same delivery vehicle is used to observe the reaction. The serial incremental dosing of the agent is. The usual sites for skin testing are the upper back, the flexor aspect of the upper arm, and the forearm.

Open test/ skin provocation test: The open test is used for the diagnosis of NICU. The test consists of gently rubbing 0.1ml of the test substance over a 3 cm x 3 cm area of intact skin on the volar aspect of the forearm. The site requires an examination at 20, 40, and 60 minutes. The best vehicle for testing the agents is an alcohol-water or alcohol propylene glycol mixture. Use test: The test agent in the same delivery vehicle is used to observe the reaction. The serial incremental dosing of the agent is. The usual sites for skin testing are the upper back, the flexor aspect of the upper arm, and the forearm. Chamber/patch test: The test substance is applied to small aluminum containers for 15 minutes and then attached to the skin using porous tape. The results are recorded at 20, 40, and 60 minutes for an immediate reaction. A delayed-type response gets assessed at 48 to 96 hours after patch application to the back. The sensitivity of this test is higher due to increased absorption by the skin. A smaller area of skin is used than in the open test. A false-positive response called 'angry back' due to active dermatitis is noted in some. A patch test is not routinely recommended because many common allergens may cause false-positive responses (e.g., balsam of Peru, parabens, sorbic acid, formaldehyde, cinnamaldehyde). Scratch test: A deep dermal scratch with the test substance is performed using the blunt bottom of a lancet after the allergen is applied to the skin; this is useful for diagnosing CU to non-standard allergens.[12] Due to the risk of anaphylaxis, it should always take place under medical supervision. Intradermal testing: uncommon due to the risk of anaphylaxis. When testing with non-standardized substances, the test controls should be assessed on at least 20 people to rule out false-positive results. Dimethyl sulfoxide (DMSO) test: The test is fast and reliable, and is used to assess the integrity of the skin barrier function. A wheal response occurs on the application of DMSO to the skin in susceptible individuals. A clinical grading is available to quantify the response (0-no reaction, 1-follicular wheal, 2-slight elevated solid wheal, 3- elevated solid, tense wheal). In-vitro test

Dimethyl sulfoxide (DMSO) test: The test is fast and reliable, and is used to assess the integrity of the skin barrier function. A wheal response occurs on the application of DMSO to the skin in susceptible individuals. A clinical grading is available to quantify the response (0-no reaction, 1-follicular wheal, 2-slight elevated solid wheal, 3- elevated solid, tense wheal). In-vitro test For the diagnosis of ICU, the presence of IgE-specific antibodies against the causative agent is used[10]. Based on the patient’s history, lab workup typically includes complete blood count (CBC), blood culture, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), basic metabolic panel (BMP), thyroid auto-antibodies, anti-nuclear antibody level (ANA) and complement levels (C3, C4) to rule out differential diagnosis like systemic illness, chronic idiopathic urticaria, autoimmune diseases, infection, etc[25].

Avoidance of the offending substance is the cornerstone of management. Patients should be educated on cross-reactive proteins and advised to avoid them if they develop symptoms on exposure. Protective gear such as gloves, skin-conditioning creams or emollients, and cotton liners is necessary when work-related exposure is unavoidable.[26][27] For patients with an allergy to NRL, alternatives such as nitrile, neoprene, and polyvinyl chloride gloves are recommended. Some of the healthcare institutions around the world have banned powdered NRL gloves at work, resulting in the decline of the incidence of CU.[28][29] For patients with CU to NRL, avoidance of all latex-containing products is recommended. Second-generation H1-receptor blockers (Ex, diphenhydramine, hydroxyzine, loratadine, desloratadine) are the first-line treatment in the ICU. Leukotriene inhibitors like montelukast, zafirlukast, and zileuton inhibit the inflammatory component.[12] Aspirin and NSAIDs are the first-line treatment options for the management of NICU. Self-administered subcutaneous epinephrine pens should be available to the patient at all times. Steroids are second-line treatment options and help to prevent the delayed phase of an anaphylactic reaction. Immunosuppressive drugs like cyclosporine and methotrexate are options in severe cases. Ultraviolet A and B light inhibit NICU reaction, and the effect can last for up to 2 weeks after treatment. It has the advantage of inhibiting skin sites that are not directly irradiated.[30] Subcutaneous immunotherapy in the management of CU is an area of research. A study on 41 bakers sensitized to wheat protein who received subcutaneous immunotherapy has shown promise as an intervention in the management of CU.[31] Immunotherapy with standardized latex extract in workers sensitized to NRL has shown improved skin reactivity.[32] A rush (2 or 4-day) sublingual desensitization to NRL has shown significant improvement in symptom scores.[33][34]

Urticaria and angioedema can be a part of systemic diseases like autoimmune disorders, endocrinopathies, malignancy, and hemolytic disease. Chronic idiopathic urticaria is usually associated with autoimmune disease. Anaphylaxis can present with generalized urticaria with other systemic symptoms. CU has overlapping features with allergic contact dermatitis, acquired angioedema, dermatographism, and irritant contact dermatitis. Glove related hand urticaria is a type of physical urticaria due to the shearing forces during the application and removal of gloves and requires differentiation from CU to NRL. Physical urticarial forms like aquagenic, cold, and solar urticaria can present similar to CU. Acute urticaria requires differentiation from erythema multiforme (with typical target lesions), toxic erythema (fixed and symmetric lesions), acute contact dermatitis, polymorphic eruption of pregnancy, and scombroid fish poisoning.[25]

Most of the patients affected by CU experience relief of symptoms with avoidance of triggers and medications. The disease duration is shorter for infants and children and prolonged when associated with other atopic diseases or with other systemic manifestations as seen in ICU.[25] Repeated exposure to the same agents may lead to a progressively severe response in ICU.

ICU has the potential to lead to life-threatening symptoms like anaphylaxis; hence, it is important to diagnose and manage these patients appropriately. Other complications include the risk of secondary bacterial infection from skin breakdown from repeated scratching.

Avoidance of the offending agent is the key-stone to disease management. For patients with allergy to NRL, avoidance or use of alternative glove materials like bamboo viscose gloves, neoprene, nitrile, or polyvinyl chloride gloves is necessary. Primary prevention strategies like avoidance of triggers, pre-employment counseling, and the implementation of personal protective equipment are prudent measures. Organizational precautions at the workplace, early disease diagnosis, and screening are other measures. Patients with CU should carry subcutaneous epinephrine pens, anti-histamine, and NSAIDs for management. Avoid scratching the skin due to the risk of introduction of extraneous bacteria leading to the risk of cellulitis or skin abscess.

Contact urticaria is an often underdiagnosed dermatological condition that is recognized as occupational dermatoses by the World Health Organisation (WHO). It requires the efforts of an interprofessional healthcare team. The general physician is usually the first point of contact for patients seeking help and knowledge of disease presentation, testing, and management can help improve the quality of life of the patients and reduce disease burden. Due to the short time taken for symptom resolution, patients usually first present after the symptoms have disappeared, making diagnosis a challenge. Referral to allergist or dermatologist is integral while managing CU. Specialists can aid in the diagnosis of atypical presentations and management of poorly-controlled cases. Nursing plays a vital role during the diagnosis procedure due to the need to monitor patients closely for anaphylaxis. CU requires an inter-disciplinary approach for optimal results. The pharmacist should review all medications and discuss potential interactions with the prescribing/treating clinician, as well as verifying all dosing. The examples of interprofessional collaboration show how this approach can improve patient outcomes. [Level 5]